ALNY Q4 2020 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+128.2% YoY

Gross Profit

$141M85.9% margin

Operating Income

-$194M-118.7% margin

Net Income

-$244M-148.9% margin

EPS (Diluted)

$-2.09

QoQ Revenue Growth

+30.0%

Cash Flow

Operating Cash Flow

-$123M

Free Cash Flow

-$145M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$2.4B

Stockholders' Equity

$1.0B

Cash & Equivalents

$497M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$72M	+128.2%
Gross Profit	$141M	$60M	+136.2%
Operating Income	-$194M	-$298M	+34.8%
Net Income	-$244M	-$276M	+11.8%

Revenue Segments

Product

$113M100%

Geographic Segments

UNITED STATES

$43M48%

Europe

$33M37%

Non-US Or Europe

$14M16%